PAR-20-225 - Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
Expired NOSIs
| Title | Notice Number | Organization | Release Date | Expiration Date | Activity Code(s) |
|---|---|---|---|---|---|
| Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases | NOT-DA-22-048 | NIDA, NCI, NIDCR | Jan 9, 2023 | Sep 9, 2025 | R01, R21, DP2, DP1, K99/R00, K01, R36, K08, R15, K24 |
For technical issues E-mail OER Webmaster